RUSSELL (CHIP) NORRIS, PhD
Assistant Professor of Cell Biology
Medical University of South Carolina
Developmental and Biomechanical Mechanisms of Cardiac Valve Tissue Formation
Mitral valve prolapse (MVP) is a major public health burden: One of the most common human diseases, it affects 1 in 40 people worldwide and is the leading indication for surgical repair for mitral regurgitation in the United States. MVP is characterized by systolic billowing of one or both mitral leaflets into the left atrium, impairing leaflet apposition (coaptation) and causing mitral regurgitation. Over time, structural changes in the valve occur due to collagen fragmentation, increased proteoglycan accumulation, aberrant myofibroblast differentiation and hyperplasia (collectively referred to as “myxomatous degeneration”). Consequentially, the leaflet becomes thicker and mechanically incompetent resulting in mitral regurgitation, frequently requiring surgical intervention to limit secondary defects including heart failure, endocarditis, and sudden cardiac death. It is clear that MVP cannot be categorized as uniformly severe or uniformly benign since patients with MVP have heterogeneous outcomes. Nearly half of the individuals diagnosed with MVP will require some aspect of intervention (surgery, medical management, etc.) and ~18% are considered high-risk with increased mortality and cardiovascular morbidity. Even though MVP has been classically viewed as an adult-onset disorder, studies of affected families indicate childhood manifestation, suggesting genetic abnormalities expressed during development become exacerbated over a lifetime. Uncovering how MVP genes regulate downstream signaling cascades will provide key mechanistic insights into how cell biology impacts normal valve mechanobiology during development and aging. The discovery and mechanistic understanding of genes causal to MVP will uncover disease etiologies and identify targeted therapeutics beneficial for patients
Etiology and Treatment of MVP: MVP can be a syndromic or non-syndromic disease. “Syndromic MVP” refers to mitral valve prolapse in the context of other structural multisystem phenotypes (e.g. Marfan Syndrome). Gene mutations that cause some rare MVP-associated connective tissue syndromes and X-linked myxomatous valvular dystrophy are known. However, the genetic underpinnings of the more common non-syndromic form of MVP has remained elusive; consequently, the etiology of the disease remains poorly understood. In collaboration with members of our previously funded Leducq Network we have identified mutations in the DCHS1 cadherin gene that segregates with mitral valve prolapse in multiple families. This is the first discovery of a gene that causes the common form of MVP in humans and is a critical step towards understanding disease etiology, pathogenesis, as well as provide new indications for remedial therapies. As curative non-surgical treatments for MVP are not currently available, these studies have potential to revolutionize medical management of the disease with outcomes expected to decrease surgical intervention, morbidity and mortality.
Our central hypothesis is that linear arrays of cells established through the activity of cell polarity genes (e.g. DCHS1) engender matrix alignment during valve development. We propose that this establishment of proper cell-ECM architecture engenders life-long valvular mechanical stability critical for proper function. This represents a novel paradigm by which valve morphogenesis proceeds and answering the question of how cell polarity engenders tissue shape and biomechanical stability is the basis of this proposal.
To test this hypothesis, molecular, cellular, and bioengineering approaches will be utilized to define how disruption of the cell polarity gene, DCHS1 perturbs normal development resulting in mitral valve prolapse in humans. Collaborations with the COBRE core facilities (Bioengineering and Bioimaging Core and Cell, Tissue, and Molecular Analysis Core) will provide unique opportunities to answer biophysical questions about heart-valve diseases that heretofore have been impossible to answer using even state-of-the-art biological and genetic approaches.
Open the original version of this page.